||Alpha synuclein is an abundant 140 amino acid neuronal protein, expressed primarily at presynaptic terminals in the central nervous system. Alpha synuclein has been associated with several neurodegenerative diseases. A point mutation in the gene coding for the alpha-synuclein protein was the first discovery linking this protein to a rare familial form of Parkinson's disease (PD). Subsequently, other mutations in the alpha-synuclein gene have been identified in familial PD. The aggregated proteinaceous inclusions called Lewy bodies found in PD and cortical Lewy body dementia (LBD) were discovered to be predominantly alpha-synuclein. Aberrant aggregation of alpha-synuclein has been detected in an increasing number of neurodegenerative diseases, collectively known as synucleopathies. Alpha-synuclein exists physiologically in both soluble and membrane-bound states, in unstructured and alpha-helical conformations, respectively. The physiological function of alpha-synuclein appears to require its translocation between these subcellular compartments and interconversion between the 2 conformations. Abnormal processing of alpha-synuclein is predicted to lead to pathological changes in its binding properties and function.
||See product label
||A synthetic peptide (CMPVDPDNEAYEMPSEE) as part of human alpha synuclein (aa: 116-131) conjugated to KLH has been used as the immunogen.
||Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP
||IHC with 1:1000 to 1:2000 dilution. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
||Immunohistochemistry shows a high specificity for alpha-synuclein.
||This antibody is known to react with human, rat and mouse alpha-synuclein.
||If you would like to use this product in another species other than those specified here, or to see the shared identity between the immunogen used here in different speices and/or other molecules, simply copy the immunogen (from the Immunogen field) and paste it HERE and blast/format it. Note that, antisera raised against synthetic peptides are quite often very specific for that peptide ie, only one single amino acid difference may be enough to restrict the specificity to a particular molecule. Regardless, you can always contact us if you need assistance with this.
||Reconstitute in 100 uL of sterile water. Centrifuge to remove any insoluble material.
||After reconstitution keep aliquots at -20C for a higher stability, and at 2-8C with an appropriate antibacterial agent. Glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles.
||12 months after purchase
||Zhang W et al. (2020) "Contribution of Alzheimer’s Disease Neuropathologic Change to the Cognitive Dysfunction in Human Brains with Lewy Body-Related Pathology."Neurobiol. Aging [In press]; Application: IHC Species: Human
||1. Lundvig, et al Brain Res Mol Brain Res 134, 3-17 (Mar 24, 2005).
2. Bennett, Pharmacol Ther 105, 311-31 (Mar, 2005).
3. Vekrellis, et al., Mol Neurobiol 30, 1-21 (Aug, 2004).
4. Martin, et al., Protein Pept Lett 11, 229-37 (Jun, 2004).
5. Doherty, et al., Acta Neuropathol (Berl) 107, 169-75 (Feb, 2004).
6. Goedert, Curr Opin Genet Dev 11, 343-51 (Jun, 2001).
7. Saito, et al., J Neurol Sci 177, 48-59 (Aug 1, 2000).
8. Lücking C.B. et al., Cell Mol Life Sci. 2000 Dec;57(13-14):1894-908.
9. Kahle, et al., Ann N Y Acad Sci 920, 33-41 (2000).
10. Clayton, et al., Trends Neurosci 21, 249-54 (Jun, 1998).